Outcomes

What were the main findings from the study?

• MICARDIS^® and amlodipine, in combination with hydrochlorothiazide (HCTZ), produced similar reductions in SBP in the last 6 hours of the dosing interval in elderly patients with ISH.⁵
• MICARDIS^® plus HCTZ reduced 24-hour mean SBP to a significantly greater extent than amlodipine plus HCTZ.⁵
• Significantly more elderly patients with ISH had their 24-hour SBP controlled (defined as <140 mmHg at week 14) with MICARDIS^® combination treatment than with amlodipine.⁵
• MICARDIS^® plus HCTZ demonstrated a significantly better side-effect profile and was associated with fewer discontinuations.⁵
• The reduction in blood pressure is large, and likely to be clinically meaningful.

MICARDIS^® plus HCTZ was significantly more effective than amlodipine plus HCTZ at reducing SBP over 24 hours, and during the morning and daytime. MICARDIS^® and amlodipine were similarly effective in reducing SBP in the last 6 hours of the dosing

MICARDIS^® plus HCTZ was significantly more effective than amlodipine plus HCTZ at reducing SBP over the 24-hour period, particularly in the first 18 hours of the dosing interval 

MICARDIS^® plus HCTZ controlled SBP (<140 mmHg at week 14) over 24-hours in a significantly higher proportion of patients

There were more adverse events in the amlodipine group than in the MICARDIS^® group. The most frequent adverse event was peripheral oedema. This led to a higher overall discontinuation due to adverse events in the amlodipine group

References